Close
Clinical Trials
AALL1732, A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (CTMS# 19-0169)
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Anne–Marie Langevin MD